Legend Biotech Corp. · NASDAQ:LEGN
Legend Biotech — Q4 2020 Earnings Presentation
15 slides from Legend Biotech's earnings presentation, Mar 18, 2021
Slide 1: Fourth Quarter 2020 Results
Fourth Quarter 2020 ResultsMarch 18, 2021
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by Legend Biotech Corporation (“Legend Biotech” or the “Company”) solely for informational purposes and does not contain all relevant information relating to the Company. The safety and efficacy of the agents and/or uses under investigation discussed in
Slide 3: Agenda
Agenda 3 Near-Term Targets for Legend Biotech Q&A CEO Opening Remarks and 2020 Financial Results “2020 was a very successful year highlighted by solid financial performance as we expanded our pipeline, built a robust team to support our multiple platforms for fighting debilitating diseases, and we c
Slide 4: 4th Quarter 2020 and Most Recent Company Highlights
4 Phase 1b/2 Study Data of Cilta-cel (CARTITUDE-1) Data continued to show a very high overall response rate that deepened over time with 97% of patients achieving an overall response and 67% of patients achieving a stringent complete response (sCR) at a median follow-up of 12.4 monthsDemonstrated a
Slide 5: Year Over Year Comparison
Year Over Year Comparison 160,000 100,000 50,000 0 50,000 100,000 180,000 200,000 280,000 300,000 -360,000 Net Loss (USD $'000) ($2,784) ($132,972) ($303,718) 2018 2019 2020 1.00 -1.00 (0.01) 2018 EPS ($0.66) ($1.29) 2019 2020 ¢ OLEGEND
Slide 6: Quarter Over Quarter Comparison
Quarter Over Quarter Comparison 6
Slide 7: Robust Pipeline of Next-Generation Cell Therapies
Robust Pipeline of Next-Generation Cell Therapies 7 InfectiousDiseases SolidTumors Preclinical Phase 1 Phase 2 Phase 3 Autologous TCL(CD4) NHL-DLBCL(CD19 x CD22) AML(CD33 x CLL-1) MM*(BCMA) Allogeneic NHL-DLBCL, FL, MCL, SLL (CD20) HIV (Undisclosed) LEGEND-2 CARTITUDE-4 Pancreatic Cancer(Claudin 18.
Slide 8: CARTITUDE-1: Early, Deep Responses and High Response Rate
8 CARTITUDE-1: Early, Deep Responses and High Response Rate Data cut-off: 01 Sept 2020; aPR or better, Independent Review Committee assessed. bNo patient had CR or stable disease as best response. cMRD was assessed in evaluable samples at 10-5 threshold by next-generation sequencing (clonoSEQ, Adapt
Slide 9: Near-Term Targets for Legend Biotech
Near-Term Targets for Legend Biotech 9 File BLA in China for cilta-cel Target FDA approval for cilta-cel in US 1H21 2H21 US: United States; BLA: Biologics License Application; FDA: Federal Drug Administration; MAA: Marketing Authorization Application; EMA: European Medicines Agency Initiate phase 1
Slide 10: Near-Term Targets for Legend Biotech
10 Target CDE approval for cilta-cel in China 2022 Target EMA approval for cilta-cel in EU 2022 Near-Term Targets for Legend Biotech File NDA to the Japan Ministry of Health, Labor and Welfare for cilta-cel 2H21
Slide 11: Data Update
Data Update Legend Biotech anticipates supporting investigators with publishing a clinical data update from LEGEND-2 study in 2021 SLEGEND ,,
Slide 12: Clinical Program: Cilta-cel Studies in Multiple Myeloma
Clinical Program: Cilta-cel Studies in Multiple Myeloma 12 DPd=daratumumab, pomalidomide, dexamethasone; EU=European Union; JP=Japan; PVd=pomalidomide, bortezomib, dexamethasone; RRMM=relapsed and/or refractory multiple myeloma; SoC=standard of care; US=United States. 1 NCT03090659. Clinicaltrials.g
Slide 13: Q&A Session
Q&A Session
Slide 14: In the world of cell therapy, some biotechs have an Eastern perspective
Inthe world of cell therapy, some biotechs have an Eastern perspective. Others have a Western perspective.
Slide 15: Thank You!
Thank You ! BIOTECH